Q-omics provides the consensus-scored TTC37 profile across patient tissues and cancer cell-line models. TTC37 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC37 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, TTC37 RNA expression shows 20,728 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where TTC37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC37 survival associations across molecular data types. TTC37 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC37 RNA expression–survival associations across cancer types. High TTC37 expression shows unfavorable associations in STAD, CESC, LGG and UVM, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC37 RNA expression.
This table summarizes TTC37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TTC37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC37 shows lower tumor expression in THCA, LUSC and KICH and higher tumor expression in LIHC, CHOL and KIRC. The LIHC box plot shows higher TTC37 RNA expression in tumor versus normal tissue (log2 FC = +1.006, t-test p < 0.001).
This table shows molecular features associated with TTC37 in patient tissues and cancer cell lines. In patient samples, TTC37 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
